MYCOLab Ai Logo - gold and army green

Styrylpyrones from Phellinus linteus Mycelia Alleviate Non-Alcoholic Fatty Liver by Modulating Lipid and Glucose Metabolic Homeostasis in High-Fat and High-Fructose Diet-Fed Mice

Summary

This research investigated how an extract from the medicinal mushroom Phellinus linteus could help treat fatty liver disease. The scientists found that compounds from this mushroom can reduce fat accumulation in the liver and help control blood sugar levels in mice fed a high-fat diet. This discovery is important for everyday life in several ways: • Could lead to new natural treatments for fatty liver disease, which affects about 25% of people worldwide • Demonstrates the potential health benefits of medicinal mushrooms in treating modern lifestyle diseases • Offers a possible dietary supplement approach to help prevent and manage fatty liver disease • Shows promise for helping people maintain healthy liver function while eating modern diets • Highlights how traditional Asian medicines can be scientifically validated for modern medical use

Background

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases worldwide and is expected to become the leading cause of end-stage liver disease in coming decades. Phellinus linteus (PL), an edible and medicinal mushroom containing styrylpyrone-type polyphenols, has shown broad bioactivities but its effects against NAFLD remain unclear.

Objective

To investigate whether ethyl acetate fraction from PL mycelia (PL-EA) is effective against NAFLD and elucidate its underlying mechanisms using both in vivo and in vitro models.

Results

PL-EA significantly reduced body weight gain, hepatic lipid accumulation, and fasting glucose levels in HFD-fed mice. It upregulated pgc-1α, sirt1 genes and adiponectin while downregulating gck and srebp-1c. Key proteins including PPARγ, pAMPK, and PGC-1α were upregulated while SREBP-1 and NF-κB were downregulated. The major compounds hispidin and hypholomine B significantly reduced oleic/palmitic acid-induced lipid accumulation in HepG2 cells through modulation of lipogenesis and energy metabolism genes.

Conclusion

PL-EA demonstrates promising therapeutic potential against NAFLD by modulating lipid and glucose metabolism through multiple pathways. The active compounds hispidin and hypholomine B contribute to these beneficial effects. Further investigation of PL-EA for treating NAFLD is warranted.
  • Published in:Antioxidants,
  • Study Type:Experimental Study,
  • Source: 10.3390/antiox11050898
Scroll to Top